Sino Biopharmaceutical (HK:1177) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Sino Biopharmaceutical has received approval to submit a marketing application for its innovative drug combination, Benmelstobart Injection and Anlotinib Hydrochloride Capsules, aimed at treating the ultra-rare alveolar soft part sarcoma (ASPS). With a high tendency for metastasis and limited treatment options, this new combination therapy offers hope for improved outcomes in ASPS patients. This development marks a significant step for Sino Biopharmaceutical in expanding its portfolio of effective cancer treatments.
For further insights into HK:1177 stock, check out TipRanks’ Stock Analysis page.